Stendra / Avanafil & the OTC-Switch Bid
The fast-onset PDE5 inhibitor and Petros Pharmaceuticals' Rx-to-OTC push
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- FDA Approved (avanafil/Stendra, 2012)
Reference only. Not medical advice.
What can go wrong
Same class safety profile: absolute contraindication with nitrates, caution with alpha-blockers, risk of hypotension, headache, flushing, and rare priapism or NAION. An OTC version would raise the stakes on self-screening for the nitrate contraindication and undiagnosed cardiovascular disease, the central safety question in any Rx-to-OTC switch for this class.
This is something to take to a clinician. The Atlas can tell you what is known about stendra / avanafil & the otc-switch bid in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Avanafil (Stendra) is the most recently FDA-approved oral PDE5 inhibitor (2012), marketed for rapid onset, labeling allows dosing as early as ~15 minutes before activity, and high PDE5 selectivity that may reduce some visual/back-pain effects. Commercially it has struggled against cheap generic sildenafil/tadalafil. Its US rights-holder, Petros Pharmaceuticals (PTPI), has pursued an FDA Rx-to-OTC switch for Stendra, running consumer self-selection studies; an OTC PDE5 inhibitor would be a significant market event.
The newest oral PDE5 inhibitor, betting its future on going over-the-counter.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Like other PDE5 inhibitors, avanafil blocks phosphodiesterase type 5, preserving cGMP and sustaining cavernosal smooth-muscle relaxation during arousal. It is marketed as highly PDE5-selective with rapid absorption, which underlies its fast onset and the claim of fewer off-target effects (e.g., less visual disturbance than sildenafil, less back pain than tadalafil).
What people get wrong
Often saidStendra is just an expensive Viagra
ActuallyAvanafil is a distinct PDE5 inhibitor with faster onset and high selectivity, but it competes against far cheaper generics, which is why its differentiation push is about OTC access, not a new mechanism.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Set against the alternatives
Avanafil's selling point is speed and selectivity; its commercial problem is price, generic sildenafil and tadalafil are far cheaper, and tadalafil offers a long duration and daily option avanafil does not. Petros's OTC-switch strategy is an attempt to differentiate on access rather than pharmacology.
At a glance
- Approved
- 2012 (avanafil/Stendra)
- Onset
- As early as ~15 minutes per labeling
- US rights
- Originally Metuchen, now Petros Pharmaceuticals (PTPI)
- Strategic play
- Rx-to-OTC switch attempt
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Stendra / Avanafil & the OTC-Switch Bid. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.